格隆汇1月21日丨里昂发表报告指,药明康德(2359.HK)管理层在电话会议上,对2022年的收入增长作出新的指导,即按年增长45%左右。同时指导2022年的净利润增长与收入增长同步,主要由药明康德的综合CRDMO(合同研究、开发及生产业务)业务模式,特别是药明康德化学业务的收入贡献所推动。 里昂将药明康德2021至2022年的收入和净利润预测提高1%至3%,以反映管理层的最新指导。同时保持2023年的收入和净利润预测不变,2024年至2031年的收入预测就削减3%至5%。目标价由202港元降至192港元,按现金流折现率作估值,重申“买入”评级。
大行评级 | 里昂:重申药明康德(2359.HK)买入评级 目标价192港元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.